BAE Systems’ Active Inceptors Earn Certification on Gulfstream G600 and G500
3.12.2019 17:00:00 EET | Business Wire | Press release
BAE Systems reached a critical milestone today with the certification of its active inceptors for Gulfstream’s G600 and G500 aircraft. The certifications are from the Federal Aviation Administration for the G600 aircraft and European Aviation Safety Agency for the G500 aircraft. The achievement marks the second series of certifications for BAE Systems’ active sticks in civil applications, which were first certified on Gulfstream’s G500 aircraft last year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191203005196/en/
BAE Systems has been a world leader in active inceptor technology for more than 25 years. (Photo: BAE Systems, Inc.)
“Our active inceptors will provide pilots of these aircraft with increased situational awareness and enable enhanced handling to maintain a safe and stable flight of Gulfstream’s G500 and G600 aircraft,” said Ehtisham Siddiqui, vice president and general manager of Controls & Avionics Solutions at BAE Systems.
Unlike a passive system, active inceptors, which are part of the controls pilots use to fly an aircraft, have electronically controlled actuators that send tactile feedback to the pilot through the stick. The feedback is programmable for specific aircraft depending on customer requirements, and can warn pilots of impending structural or aerodynamic operating limits. One of the key benefits of active inceptors is the ability to link the pilot and co-pilot controls, so each can see and feel the other’s control inputs in real time.
BAE Systems has been a world leader in active inceptor technology for more than 25 years. The military version of the technology was originally developed for the Joint Strike Fighter program in the 1990s, achieving its first flight on the platform in 2000 and becoming the world’s first certified military active inceptor on the F-35 just six years later. That same core technology achieved a handful of other world firsts, which includes first flight on helicopters such as Blackhawk and Chinook. Today, the company’s active inceptors have flown on 12 different commercial and military aircraft around the world and have logged more than 200,000 flight hours.
BAE Systems is a premier provider of advanced and affordable controls, avionics, and power management systems for aircraft. From controlling the aircraft to keeping its engine running at peak performance, BAE Systems serves more than two million passengers each day. Every second of every day a plane safely takes off and lands because of its products.
For more information, visit: http://www.baesystems-ps.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191203005196/en/
Contact information
BAE Systems
Anthony DeAngelis
Office: +1 603-885-4922
Mobile: +1 603-714-3664
anthony.deangelis@baesystems.com
Amanda Desourdis
Office: +44 (0)3300 485771
Mobile: +44 (0)7990 623358
amanda.desourdis3@baesystems.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data include an oral proffered paper presentation on BeOne’s GPC3x4-1BB bispecific antibody, currently being studied in hepatocellular carcinoma (HCC) and first-in-human data for two investigational lung cancer assets, a CEA targeting antibody-drug conjugate (ADC), in CEA-expressing non-small cell lung cancer (NSCLC), and a brain-penetrant PRMT5 inhibitor in MTAP-deleted tumors, inclu
The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Experts in Vienna19.10.2026 13:00:00 EEST | Press release
Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent challenge: transforming Europe's data centre energy landscape. We brought together leaders from across the data ce
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO ® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 12:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically relevant target in the treatment of moderate to severe ulcerative colitis.1 Results were presented during late-breaker and poster sessions at United European Gastroenterology (UEG) Week 2026 and published in the United European Gastroenterology Journal. “There has been increasing conversation about whether achieving deeper levels of remission – addressing both visible and microscopic inflammation
Boomi Acquires Elementary Data to Bring Trusted, Governed Data to the AI Era19.10.2026 12:00:00 EEST | Press release
Boomi, the data activation company for AI, today announced it has acquired Elementary Data, a provider of the widely adopted data observability solution that powers every workflow and AI agent with reliable data. Following Lunar.dev, Elementary is Boomi’s latest acquisition, strengthening the Boomi Enterprise Platform with the observability, quality, governance, and discovery capabilities enterprises need to deliver trusted data for AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019376249/en/ Boomi Acquires Elementary Data to Bring Trusted, Governed Data to the AI Era Key Takeaways What Boomi acquired. Elementary provides unified observability, quality, governance, and discovery. Founded in 2022, Elementary began as an open-source project — now adopted by 1,500+ data teams, with 1.1M + monthly downloads, and a ~4,000-member community. In 2024, it launched Elementary Cloud which added enterprise-grade capabilities on t
Reply Earns “NVIDIA Physical AI Specialization” for Production-Ready Robotics and Digital Twins19.10.2026 11:00:00 EEST | Press release
Reply [EXM, STAR: REY] is among the first NVIDIA partners in the world to achieve the “Physical AI Specialization” within the NVIDIA Partner Network (NPN), in recognition of its expertise in developing and deploying AI-driven robotics and digital twin solutions for real-world operating environments. The specialization was awarded following a technical assessment covering a customer implementation, solution architecture, certified OpenUSD expertise and Reply’s development roadmap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019881053/en/ Reply is among the first NVIDIA partners in the world to achieve the “Physical AI Specialization” within the NVIDIA Partner Network (NPN), in recognition of its expertise in developing and deploying AI-driven robotics and digital twin solutions for real-world operating environments. Physical AI is becoming increasingly relevant in manufacturing, warehousing and logistics as companies mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
